Hemostatic Disorder Clinical Trial
Official title:
A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. However, the minor and major bleeding events has not been described yet. We observe the patients' major and minor bleeding events and use 4 criteria, which include BARC, ISTH, TIMI, Gusto ,to evaluate the incident rate of bleeding events in ACLF patients and pre-ACLF patients.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | September 16, 2017 |
Est. primary completion date | September 16, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - patient with previously or undiagnosed chronic liver disease/cirrhosis; - serum bilirubin higher than 3 mg/dl (51 mmol/L) or ALT>10ULN(male 300 U/L; female 200 U/L) Exclusion Criteria: - those who had or been diagnosed hepatocellular carcinoma or other types of malignancies; - pregnancy; - obstructive biliary diseases or other disease lead to bilirubin evaluation; - using steroid or immunosuppressant in 4 weeks; - prior surgeries including splenectomy,subtotal splenectomy and disconnection,liver transplantation. - combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure(PaO2<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS<8) |
Country | Name | City | State |
---|---|---|---|
China | Nanfang Hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Nanfang Hospital of Southern Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 28-day progression | progressed to EASL or APASL defined ACLF or death | 28-day | |
Secondary | major bleeding event | major bleeding event happen | 90-day | |
Secondary | 28-day mortality | death within 28 days | 28-day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Recruiting |
NCT04600609 -
Examining the Experiences of Children With Blood Disorders
|
||
Active, not recruiting |
NCT04309084 -
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
|
Phase 1 | |
Completed |
NCT04757285 -
Copeptin and Psychological Stress of Medic During COVID-19 Pandemic
|
||
Terminated |
NCT04729946 -
Clinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System
|
N/A | |
Not yet recruiting |
NCT06242353 -
Coagulopathy in Childhood Acute Lymphoblastic Leukaemia
|
||
Completed |
NCT04499612 -
Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
|
||
Not yet recruiting |
NCT06328647 -
Quantra Point-of-Care Hemostasis Monitoring
|
N/A | |
Not yet recruiting |
NCT04179357 -
Hemostatic Disorders on Intensive Care Patients.
|
||
Recruiting |
NCT04650529 -
Gyeongsang National University Hospital Registry
|
||
Completed |
NCT03756948 -
Viscoelastic Tests-Guided Therapy In Liver Transplantation
|
N/A | |
Recruiting |
NCT05476458 -
To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
|
||
Recruiting |
NCT04762576 -
Thrombin in Cardiac Surgery
|
||
Completed |
NCT03555383 -
Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)
|
||
Terminated |
NCT03806556 -
A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
|
Phase 1/Phase 2 |